The new results highlight Revitas potential as a compelling first-in-class therapy for post-GLP-1 weight maintenance
Market opportunities and emerging innovations: As GLP-1 adoption expands, industries face shifting demand across health, nutrition, and behavioral needs
These results have been successfully replicated in studies using other animal models
Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, et al
This is a thread we could pull in many directions, but for our purposes today the important point is simply that glucose is the primary fuel source for the brain and for working muscle, and managing its availability is a high-stakes process
If retatrutide works as well as early trials suggest, it shouldnt be too long to wait for FDA review and a real prescription version